ABBV•benzinga•
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
Summary
AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 3, 2025 by benzinga